Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001

References

• Harley CB, Kim NW, Prowse KR, Weinrich SL, Hirsch KS, West MD, et al. Telomerase, cell immortality, and cancer. Cold Spring Harb Symp Quant Biol 1994; 59:307 - 15; http://dx.doi.org/10.1101/SQB.1994.059.01.035; PMID: 7587082
   PubMedGoogle Scholar
• Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266:2011 - 5; http://dx.doi.org/10.1126/science.7605428; PMID: 7605428
   PubMed Web of Science ®Google Scholar
• Shay JW. Telomerase in human development and cancer. J Cell Physiol 1997; 173:266 - 70; http://dx.doi.org/10.1002/(SICI)1097-4652(199711)173:2<266::AID-JCP33>3.0.CO;2-B; PMID: 9365534
   PubMed Web of Science ®Google Scholar
• Counter CM, Meyerson M, Eaton EN, Ellisen LW, Caddle SD, Haber DA, et al. Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene 1998; 16:1217 - 22; http://dx.doi.org/10.1038/sj.onc.1201882; PMID: 9528864
   PubMed Web of Science ®Google Scholar
• Ho MM, Ng AV, Lam S, Hung JY. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 2007; 67:4827 - 33; http://dx.doi.org/10.1158/0008-5472.CAN-06-3557; PMID: 17510412
   PubMed Web of Science ®Google Scholar
• Karimi-Busheri F, Rasouli-Nia A, Mackey JR, Weinfeld M. Senescence evasion by MCF-7 human breast tumor-initiating cells. Breast Cancer Res 2010; 12:R31; http://dx.doi.org/10.1186/bcr2583; PMID: 20525204
   PubMedGoogle Scholar
• Marian CO, Cho SK, McEllin BM, Maher EA, Hatanpaa KJ, Madden CJ, et al. The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth. Clin Cancer Res 2010; 16:154 - 63; http://dx.doi.org/10.1158/1078-0432.CCR-09-2850; PMID: 20048334
   PubMed Web of Science ®Google Scholar
• Marian CO, Wright WE, Shay JW. The effects of telomerase inhibition on prostate tumor-initiating cells. Int J Cancer 2010; 127:321 - 31; PMID: 19908230
   PubMed Web of Science ®Google Scholar
• Aloysius MM, Mc Kechnie AJ, Robins RA, Verma C, Eremin JM, Farzaneh F, et al. Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs. J Transl Med 2009; 7:18; http://dx.doi.org/10.1186/1479-5876-7-18; PMID: 19298672
   PubMed Web of Science ®Google Scholar
• Chen DY, Vance BA, Thompson LB, Domchek SM, Vonderheide RH. Differential lysis of tumors by polyclonal T cell lines and T cell clones specific for hTERT. Cancer Biol Ther 2007; 6:1991 - 6; http://dx.doi.org/10.4161/cbt.6.12.5078; PMID: 18087213
   PubMed Web of Science ®Google Scholar
• Vonderheide RH, Domchek SM, Schultze JL, George DJ, Hoar KM, Chen DY, et al. Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res 2004; 10:828 - 39; http://dx.doi.org/10.1158/1078-0432.CCR-0620-3; PMID: 14871958
   PubMed Web of Science ®Google Scholar
• Wenandy L, Sørensen RB, Sengeløv L, Svane IM. thor Straten P, Andersen MH. The immunogenicity of the hTERT540-548 peptide in cancer. Clin Cancer Res 2008; 14:4 - 7; http://dx.doi.org/10.1158/1078-0432.CCR-07-4590; PMID: 18172245
   PubMed Web of Science ®Google Scholar
• Bernhardt SL, Gjertsen MK, Trachsel S, Møller M, Eriksen JA, Meo M, et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study. Br J Cancer 2006; 95:1474 - 82; http://dx.doi.org/10.1038/sj.bjc.6603437; PMID: 17060934
   PubMed Web of Science ®Google Scholar
• Brunsvig PF, Aamdal S, Gjertsen MK, Kvalheim G, Markowski-Grimsrud CJ, Sve I, et al. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol Immunother 2006; 55:1553 - 64; http://dx.doi.org/10.1007/s00262-006-0145-7; PMID: 16491401
   PubMed Web of Science ®Google Scholar
• Domchek SM, Recio A, Mick R, Clark CE, Carpenter EL, Fox KR, et al. Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance. Cancer Res 2007; 67:10546 - 55; http://dx.doi.org/10.1158/0008-5472.CAN-07-2765; PMID: 17974999
   PubMed Web of Science ®Google Scholar
• Su Z, Dannull J, Yang BK, Dahm P, Coleman D, Yancey D, et al. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol 2005; 174:3798 - 807; PMID: 15749921
   PubMed Web of Science ®Google Scholar
• Parkhurst MR, Riley JP, Igarashi T, Li Y, Robbins PF, Rosenberg SA. Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase. Clin Cancer Res 2004; 10:4688 - 98; http://dx.doi.org/10.1158/1078-0432.CCR-04-0325; PMID: 15269141
   PubMed Web of Science ®Google Scholar
• Kyte JA, Gaudernack G, Dueland S, Trachsel S, Julsrud L, Aamdal S. Telomerase peptide vaccination combined with temozolomide: a clinical trial in stage IV melanoma patients. Clin Cancer Res 2011; 17:4568 - 80; http://dx.doi.org/10.1158/1078-0432.CCR-11-0184; PMID: 21586625
   PubMed Web of Science ®Google Scholar
• Hunger RE, Kernland Lang K, Markowski CJ, Trachsel S, Møller M, Eriksen JA, et al. Vaccination of patients with cutaneous melanoma with telomerase-specific peptides. Cancer Immunol Immunother 2011; 60:1553 - 64; http://dx.doi.org/10.1007/s00262-011-1061-z; PMID: 21681371
   PubMed Web of Science ®Google Scholar
• Kyte JA, Trachsel S, Risberg B. thor Straten P, Lislerud K, Gaudernack G. Unconventional cytokine profiles and development of T cell memory in long-term survivors after cancer vaccination. Cancer Immunol Immunother 2009; 58:1609 - 26; http://dx.doi.org/10.1007/s00262-009-0670-2; PMID: 19221745
   PubMed Web of Science ®Google Scholar
• Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2002; 2:85 - 95; http://dx.doi.org/10.1038/nri724; PMID: 11910899
   PubMed Web of Science ®Google Scholar
• Le Bon A, Etchart N, Rossmann C, Ashton M, Hou S, Gewert D, et al. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol 2003; 4:1009 - 15; http://dx.doi.org/10.1038/ni978; PMID: 14502286
   PubMed Web of Science ®Google Scholar
• Ribas A, Timmerman JM, Butterfield LH, Economou JS. Determinant spreading and tumor responses after peptide-based cancer immunotherapy. Trends Immunol 2003; 24:58 - 61; http://dx.doi.org/10.1016/S1471-4906(02)00029-7; PMID: 12547500
   PubMed Web of Science ®Google Scholar
• Gondek DC, Lu LF, Quezada SA, Sakaguchi S, Noelle RJ. Cutting edge: contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J Immunol 2005; 174:1783 - 6; PMID: 15699103
   PubMed Web of Science ®Google Scholar
• Zhao DM, Thornton AM, DiPaolo RJ, Shevach EM. Activated CD4+CD25+ T cells selectively kill B lymphocytes. Blood 2006; 107:3925 - 32; http://dx.doi.org/10.1182/blood-2005-11-4502; PMID: 16418326
   PubMed Web of Science ®Google Scholar
• Yanai F, Ishii E, Kojima K, Hasegawa A, Azuma T, Hirose S, et al. Essential roles of perforin in antigen-specific cytotoxicity mediated by human CD4+ T lymphocytes: analysis using the combination of hereditary perforin-deficient effector cells and Fas-deficient target cells. J Immunol 2003; 170:2205 - 13; PMID: 12574394
   PubMed Web of Science ®Google Scholar
• Suso EM, Dueland S, Rasmussen AM, Vetrhus T, Aamdal S, Kvalheim G, et al. hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes. Cancer Immunol Immunother 2011; 60:809 - 18; http://dx.doi.org/10.1007/s00262-011-0991-9; PMID: 21365467
   PubMed Web of Science ®Google Scholar
• Schroers R, Shen L, Rollins L, Rooney CM, Slawin K, Sonderstrup G, et al. Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes. Clin Cancer Res 2003; 9:4743 - 55; PMID: 14581345
   PubMed Web of Science ®Google Scholar
• Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401:708 - 12; http://dx.doi.org/10.1038/44385; PMID: 10537110
   PubMed Web of Science ®Google Scholar
• Romero P, Zippelius A, Kurth I, Pittet MJ, Touvrey C, Iancu EM, et al. Four functionally distinct populations of human effector-memory CD8+ T lymphocytes. J Immunol 2007; 178:4112 - 9; PMID: 17371966
   PubMed Web of Science ®Google Scholar
• Ben-Smith A, Gorak-Stolinska P, Floyd S, Weir RE, Lalor MK, Mvula H, et al. Differences between naive and memory T cell phenotype in Malawian and UK adolescents: a role for Cytomegalovirus?. BMC Infect Dis 2008; 8:139 - 48; http://dx.doi.org/10.1186/1471-2334-8-139; PMID: 18922182
   PubMed Web of Science ®Google Scholar
• Harrington LE, Janowski KM, Oliver JR, Zajac AJ, Weaver CT. Memory CD4 T cells emerge from effector T-cell progenitors. Nature 2008; 452:356 - 60; http://dx.doi.org/10.1038/nature06672; PMID: 18322463
   PubMed Web of Science ®Google Scholar
• Brunsvig PF, Kyte JA, Kersten C, Sundstrøm S, Møller M, Nyakas M, et al. Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial. Clin Cancer Res 2011; 17:6847 - 57; http://dx.doi.org/10.1158/1078-0432.CCR-11-1385; PMID: 21918169
   PubMed Web of Science ®Google Scholar
• Kayagaki N, Yamaguchi N, Nakayama M, Kawasaki A, Akiba H, Okumura K, et al. Involvement of TNF-related apoptosis-inducing ligand in human CD4+ T cell-mediated cytotoxicity. J Immunol 1999; 162:2639 - 47; PMID: 10072506
   PubMed Web of Science ®Google Scholar
• Disis ML, Grabstein KH, Sleath PR, Cheever MA. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res 1999; 5:1289 - 97; PMID: 10389911
   PubMed Web of Science ®Google Scholar
• Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 2002; 20:2624 - 32; http://dx.doi.org/10.1200/JCO.2002.06.171; PMID: 12039923
   PubMed Web of Science ®Google Scholar
• Disis ML, Wallace DR, Gooley TA, Dang Y, Slota M, Lu H, et al. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol 2009; 27:4685 - 92; http://dx.doi.org/10.1200/JCO.2008.20.6789; PMID: 19720923
   PubMed Web of Science ®Google Scholar
• Appay V, Zaunders JJ, Papagno L, Sutton J, Jaramillo A, Waters A, et al. Characterization of CD4(+) CTLs ex vivo. J Immunol 2002; 168:5954 - 8; PMID: 12023402
   PubMed Web of Science ®Google Scholar
• Deffrennes V, Vedrenne J, Stolzenberg MC, Piskurich J, Barbieri G, Ting JP, et al. Constitutive expression of MHC class II genes in melanoma cell lines results from the transcription of class II transactivator abnormally initiated from its B cell-specific promoter. J Immunol 2001; 167:98 - 106; PMID: 11418637
   PubMed Web of Science ®Google Scholar
• Wedén S, Klemp M, Gladhaug IP, Møller M, Eriksen JA, Gaudernack G, et al. Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras. Int J Cancer 2011; 128:1120 - 8; http://dx.doi.org/10.1002/ijc.25449; PMID: 20473937
   PubMed Web of Science ®Google Scholar
• Williams MA, Ravkov EV, Bevan MJ. Rapid culling of the CD4+ T cell repertoire in the transition from effector to memory. Immunity 2008; 28:533 - 45; http://dx.doi.org/10.1016/j.immuni.2008.02.014; PMID: 18356084
   PubMed Web of Science ®Google Scholar
• Charo J, Perez C, Buschow C, Jukica A, Czeh M, Blankenstein T. Visualizing the dynamic of adoptively transferred T cells during the rejection of large established tumors. Eur J Immunol 2011; 41:3187 - 97; http://dx.doi.org/10.1002/eji.201141452; PMID: 21898380
   PubMed Web of Science ®Google Scholar
• Xie Y, Akpinarli A, Maris C, Hipkiss EL, Lane M, Kwon EK, et al. Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J Exp Med 2010; 207:651 - 67; http://dx.doi.org/10.1084/jem.20091921; PMID: 20156973
   PubMed Web of Science ®Google Scholar
• Wong SB, Bos R, Sherman LA. Tumor-specific CD4+ T cells render the tumor environment permissive for infiltration by low-avidity CD8+ T cells. J Immunol 2008; 180:3122 - 31; PMID: 18292535
   PubMed Web of Science ®Google Scholar
• Nakanishi Y, Lu B, Gerard C, Iwasaki A. CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help. Nature 2009; 462:510 - 3; http://dx.doi.org/10.1038/nature08511; PMID: 19898495
   PubMed Web of Science ®Google Scholar
• Kyte JA. Cancer vaccination with telomerase peptide GV1001. Expert Opin Investig Drugs 2009; 18:687 - 94; http://dx.doi.org/10.1517/13543780902897631; PMID: 19388882
   PubMed Web of Science ®Google Scholar
• Gjertsen MK, Saeterdal I, Saebøe-Larssen S, Gaudernack G. HLA-A3 restricted mutant ras specific cytotoxic T-lymphocytes induced by vaccination with T-helper epitopes. J Mol Med (Berl) 2003; 81:43 - 50; PMID: 12545248
   PubMed Web of Science ®Google Scholar
• Kyte JA, Kvalheim G, Aamdal S, Saebøe-Larssen S, Gaudernack G. Preclinical full-scale evaluation of dendritic cells transfected with autologous tumor-mRNA for melanoma vaccination. Cancer Gene Ther 2005; 12:579 - 91; http://dx.doi.org/10.1038/sj.cgt.7700837; PMID: 15818380
   PubMed Web of Science ®Google Scholar
• Lissina A, Ladell K, Skowera A, Clement M, Edwards E, Seggewiss R, et al. Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers. J Immunol Methods 2009; 340:11 - 24; http://dx.doi.org/10.1016/j.jim.2008.09.014; PMID: 18929568
   PubMed Web of Science ®Google Scholar